Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Down Syndrome Ups Risk for Infection-Related Death in Pediatric ALL

June 25, 2014
By Leah Lawrence
Article

Researchers have identified Down syndrome as a risk factor for infection-related mortality among pediatric patients with acute lymphoblastic leukemia.

Acute lymphoblastic leukemia

ALL smear; source: Jimjamjak, Wikimedia Commons

Researchers have identified Down syndrome as a major risk factor for infection-related mortality among pediatric patients with acute lymphoblastic leukemia (ALL) enrolled in the Medical Research Council UKALL 2003 trial.

“Our analysis demonstrated that a significant proportion of sepsis deaths occurred during induction and during periods of neutropenia,” wrote researchers led by David O’ Connor, MD, of Imperial College London. “Thus increased awareness of the potential for septic complications is required when caring for patients during these high-risk periods.”

The currently reported rates of treatment-related mortality in trials of patients with ALL is between 2% and 4%, with the most common cause being infection. With ALL having such high survival rates in low-risk patients, reducing infection-related mortality is an important goal for improving outcomes with children with this disease, according to O’Connor and colleagues.

To date, few studies have investigated risk factors for infection-related mortality in pediatric patients with ALL. In an attempt to provide more evidence, the researchers conducted this retrospective analysis of cases of infection-related mortality that occurred in patients in the large, multicenter, Medical Research Council (MRC) UKALL 2003 trial. MRC UKALL 2003 was a study of children and adolescents with ALL diagnosed at 45 centers in the United Kingdom and Ireland. Patients were aged 1 to 20 years.

For this analysis, infection-related mortality was defined as any death that occurred in the presence of clinical or microbiological documented infection. The results were published in Blood.

Among the 3,126 patients in the UKALL 2003 trial, 249 deaths occurred, including 117 (47%) from treatment-related mortality. Sepsis was identified as the most common cause of treatment-related mortality, accounting for 64.1% of all treatment-related deaths.

At 5 years, the cumulative incidence of death was 8.5% for patients in the trial; treatment-related mortality was 3.8%. The cumulative incidence of infection-related mortality was 2.4%, which equates to 30% of all trial deaths.

The researchers conducted a multivariate analysis to identify factors that were associated with an increased risk for infection-related mortality. Patients with Down syndrome had a significantly increased risk (odds ratio [OR] = 12.08; 95% CI, 6.54-22.32; P < .0001).

“Down syndrome patients were at increased risk of infection-related mortality compared to non-Down syndrome patients in all trial phases,” the researchers wrote. “However, whilst most infection-related mortality occurred in the induction phase in non-Down syndrome patients, infection-related mortality in Down syndrome patients was spread relatively evenly throughout all trial phases.”

Girls were also found to have an increased risk (OR = 1.63; 95% CI, 1.02-2.61; P = .02). In addition, patients who were treated with a higher intensity regimen also had increased risk for infection.

Sepsis was found to have occurred more commonly in the induction and post-induction phases of treatment. However, infection-related mortality made up 77.6% of the treatment-related mortality during the induction phase compared with only 56% of treatment-related mortality in other phases (P = .02).

“Bacterial infections were the leading cause of infection-related mortality,” the researchers wrote. “However, in contrast to research that has highlighted the prevalence of gram positive infections in pediatric ALL, we found that gram negative bacteria were most frequently implicated in infection-related mortality. In particular, pseudomonas was the single commonest cause of treatment-related mortality.”

Recent Videos
The pediatric care wing of the Jack & Sheryl Morris Cancer Center is intended to accommodate the physical and emotional needs of younger patients with cancer.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
5 experts in this video
Related Content
Advertisement

EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

Tim Cortese
June 3rd 2025
Article

In patients with advanced Hodgkin lymphoma, BrECADD was noninferior to eBEACOPP chemotherapy and demonstrated improved progression-free survival.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


The FDA assigned a Prescription Drug User Fee Act date of November 30, 2025, for ziftomenib in NPM1-mutant acute myeloid leukemia.

Ziftomenib Earns FDA Priority Review for R/R NPM1-Mutrant AML

Roman Fabbricatore
June 3rd 2025
Article

The FDA assigned a Prescription Drug User Fee Act date of November 30, 2025, for ziftomenib in NPM1-mutant acute myeloid leukemia.


Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.


Low Rates of Chronic Graft-Versus-Host Disease With Ruxolitinib Maintenance Following Allogeneic HCT

Low Rates of Chronic Graft-Versus-Host Disease With Ruxolitinib Maintenance Following Allogeneic HCT

American Society for Transplantation and Cellular Therapy
June 2nd 2025
Article

Researchers conducted a prospective, multicenter phase II clinical trial demonstrating that prolonged administration of ruxolitinib after allogeneic HCT is associated with notably low rates of cGVHD.


Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.

Rusfertide Combo Enhances Responses in Polycythemia Vera

Sabrina Serani
June 2nd 2025
Article

Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.

Related Content
Advertisement

EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

Tim Cortese
June 3rd 2025
Article

In patients with advanced Hodgkin lymphoma, BrECADD was noninferior to eBEACOPP chemotherapy and demonstrated improved progression-free survival.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


The FDA assigned a Prescription Drug User Fee Act date of November 30, 2025, for ziftomenib in NPM1-mutant acute myeloid leukemia.

Ziftomenib Earns FDA Priority Review for R/R NPM1-Mutrant AML

Roman Fabbricatore
June 3rd 2025
Article

The FDA assigned a Prescription Drug User Fee Act date of November 30, 2025, for ziftomenib in NPM1-mutant acute myeloid leukemia.


Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.


Low Rates of Chronic Graft-Versus-Host Disease With Ruxolitinib Maintenance Following Allogeneic HCT

Low Rates of Chronic Graft-Versus-Host Disease With Ruxolitinib Maintenance Following Allogeneic HCT

American Society for Transplantation and Cellular Therapy
June 2nd 2025
Article

Researchers conducted a prospective, multicenter phase II clinical trial demonstrating that prolonged administration of ruxolitinib after allogeneic HCT is associated with notably low rates of cGVHD.


Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.

Rusfertide Combo Enhances Responses in Polycythemia Vera

Sabrina Serani
June 2nd 2025
Article

Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.